Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Velcade and Rituximab in Relapsed/Refractory Indolent NHL and Mantle Cell Lymphoma
NCT00509379Phase 2Completed
- Sponsor
- GIMEMA
- Start
- Sep 2006
- Primary completion
- Nov 2007
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
Phase 2, open-label trial of bortezomib in non-Hodgkin lymphoma (NHL) and mantle cell lymphoma (MCL), sponsored by GIMEMA. Primary endpoint: Overall Response Rate at 1 year. Started Sep 2006; status: completed.
02
Drugs
bortezomib
03
Conditions
non-Hodgkin lymphoma (NHL)mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT00509379.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00509379.